Topical praziquantel as a new treatment for perioral dermatitis: Results of a randomized vehicle-controlled pilot study

M. R. Bribeche, V. P. Fedotov, Anand Jillella, V. V. Gladichev, D. M. Pukhalskaya

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background. Perioral dermatitis (POD) is a common skin disease, and extending the range of treatments available for this condition is important. Aim. To evaluate the safety, efficacy and tolerability of praziquantel 3% ointment as monotherapy. Methods. This was a single-centre, randomized, single-blind, vehicle-controlled pilot study in adult patients (n = 46) with 4 weeks of treatment and 4 weeks of follow-up. Efficacy was assessed clinically using the Investigator's Global Assessment (IGA) and the Perioral Dermatitis Severity Index (PODSI). Quality of life (QOL) was determined by the Dermatology Quality of Life Index (DLQI). Results. PODSI was significantly lower in the praziquantel group than in the placebo (vehicle) group, both during treatment and period. Mean IGA score showed a statistically significant therapeutic advantage of praziquantel over placebo at week 4 (P < 0.001). The praziquantel group experienced a greater improvement in mean DLQI. No serious treatment-related adverse events occurred in either group. Conclusions. Praziquantel ointment 3% effectively improves POD symptoms and QOL.

Original languageEnglish (US)
Pages (from-to)448-453
Number of pages6
JournalClinical and Experimental Dermatology
Volume39
Issue number4
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Perioral Dermatitis
Praziquantel
Quality of Life
Ointments
Dermatology
Placebos
Research Personnel
Therapeutics
Skin Diseases
Safety

ASJC Scopus subject areas

  • Dermatology

Cite this

Topical praziquantel as a new treatment for perioral dermatitis : Results of a randomized vehicle-controlled pilot study. / Bribeche, M. R.; Fedotov, V. P.; Jillella, Anand; Gladichev, V. V.; Pukhalskaya, D. M.

In: Clinical and Experimental Dermatology, Vol. 39, No. 4, 01.01.2014, p. 448-453.

Research output: Contribution to journalArticle

Bribeche, M. R. ; Fedotov, V. P. ; Jillella, Anand ; Gladichev, V. V. ; Pukhalskaya, D. M. / Topical praziquantel as a new treatment for perioral dermatitis : Results of a randomized vehicle-controlled pilot study. In: Clinical and Experimental Dermatology. 2014 ; Vol. 39, No. 4. pp. 448-453.
@article{1f5852cda3514413b2ee3c2c4c893932,
title = "Topical praziquantel as a new treatment for perioral dermatitis: Results of a randomized vehicle-controlled pilot study",
abstract = "Background. Perioral dermatitis (POD) is a common skin disease, and extending the range of treatments available for this condition is important. Aim. To evaluate the safety, efficacy and tolerability of praziquantel 3{\%} ointment as monotherapy. Methods. This was a single-centre, randomized, single-blind, vehicle-controlled pilot study in adult patients (n = 46) with 4 weeks of treatment and 4 weeks of follow-up. Efficacy was assessed clinically using the Investigator's Global Assessment (IGA) and the Perioral Dermatitis Severity Index (PODSI). Quality of life (QOL) was determined by the Dermatology Quality of Life Index (DLQI). Results. PODSI was significantly lower in the praziquantel group than in the placebo (vehicle) group, both during treatment and period. Mean IGA score showed a statistically significant therapeutic advantage of praziquantel over placebo at week 4 (P < 0.001). The praziquantel group experienced a greater improvement in mean DLQI. No serious treatment-related adverse events occurred in either group. Conclusions. Praziquantel ointment 3{\%} effectively improves POD symptoms and QOL.",
author = "Bribeche, {M. R.} and Fedotov, {V. P.} and Anand Jillella and Gladichev, {V. V.} and Pukhalskaya, {D. M.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/ced.12342",
language = "English (US)",
volume = "39",
pages = "448--453",
journal = "Clinical and Experimental Dermatology",
issn = "0307-6938",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Topical praziquantel as a new treatment for perioral dermatitis

T2 - Results of a randomized vehicle-controlled pilot study

AU - Bribeche, M. R.

AU - Fedotov, V. P.

AU - Jillella, Anand

AU - Gladichev, V. V.

AU - Pukhalskaya, D. M.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background. Perioral dermatitis (POD) is a common skin disease, and extending the range of treatments available for this condition is important. Aim. To evaluate the safety, efficacy and tolerability of praziquantel 3% ointment as monotherapy. Methods. This was a single-centre, randomized, single-blind, vehicle-controlled pilot study in adult patients (n = 46) with 4 weeks of treatment and 4 weeks of follow-up. Efficacy was assessed clinically using the Investigator's Global Assessment (IGA) and the Perioral Dermatitis Severity Index (PODSI). Quality of life (QOL) was determined by the Dermatology Quality of Life Index (DLQI). Results. PODSI was significantly lower in the praziquantel group than in the placebo (vehicle) group, both during treatment and period. Mean IGA score showed a statistically significant therapeutic advantage of praziquantel over placebo at week 4 (P < 0.001). The praziquantel group experienced a greater improvement in mean DLQI. No serious treatment-related adverse events occurred in either group. Conclusions. Praziquantel ointment 3% effectively improves POD symptoms and QOL.

AB - Background. Perioral dermatitis (POD) is a common skin disease, and extending the range of treatments available for this condition is important. Aim. To evaluate the safety, efficacy and tolerability of praziquantel 3% ointment as monotherapy. Methods. This was a single-centre, randomized, single-blind, vehicle-controlled pilot study in adult patients (n = 46) with 4 weeks of treatment and 4 weeks of follow-up. Efficacy was assessed clinically using the Investigator's Global Assessment (IGA) and the Perioral Dermatitis Severity Index (PODSI). Quality of life (QOL) was determined by the Dermatology Quality of Life Index (DLQI). Results. PODSI was significantly lower in the praziquantel group than in the placebo (vehicle) group, both during treatment and period. Mean IGA score showed a statistically significant therapeutic advantage of praziquantel over placebo at week 4 (P < 0.001). The praziquantel group experienced a greater improvement in mean DLQI. No serious treatment-related adverse events occurred in either group. Conclusions. Praziquantel ointment 3% effectively improves POD symptoms and QOL.

UR - http://www.scopus.com/inward/record.url?scp=84900406878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900406878&partnerID=8YFLogxK

U2 - 10.1111/ced.12342

DO - 10.1111/ced.12342

M3 - Article

C2 - 24825135

AN - SCOPUS:84900406878

VL - 39

SP - 448

EP - 453

JO - Clinical and Experimental Dermatology

JF - Clinical and Experimental Dermatology

SN - 0307-6938

IS - 4

ER -